Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XOMA CORPORATION

(XOMA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

XOMA Gets Orphan Drug Designation for Pancreatic Cancer Treatment

07/28/2021 | 07:42am EDT

By Chris Wack

XOMA Corp. said its NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.

The company said NIS793 is a potential first in class novel antibody specific for transforming growth factor beta.

An Orphan Drug Designation grants special status to a drug that treats a rare disease or condition and provides companies certain benefits to encourage the continued development of medicines that bring novel solutions to patients with these severe diseases.

Under the terms of a 2015 agreement between XOMA and Novartis AG, XOMA has the potential to earn up to $445 million in additional milestone payments. Upon receipt of regulatory approval to commercialize NIS793, XOMA will receive tiered royalties on any net product sales that range from the mid-single digits to the low double digits.

XOMA shares were up 15% to $38.50 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

07-28-21 0942ET

All news about XOMA CORPORATION
07:31aXOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
GL
09/20XOMA Declares Quarterly Preferred Stock Dividends
GL
09/13XOMA : to Present at H.C. Wainwright 23rd Annual Global Investment Conference
AQ
09/09XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating
MT
09/08NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/07XOMA : Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41
MT
09/02XOMA CORP : Other Events (form 8-K)
AQ
08/11EQS-ADHOC : Kuros Biosciences Reports Results for First Half 2021
DJ
08/10XOMA : Departure of Directors or Certain Officers; Election of Directors; Appointment of C..
PU
08/10XOMA CORP : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on XOMA CORPORATION
More recommendations
Financials (USD)
Sales 2021 9,96 M - -
Net income 2021 -11,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -23,2x
Yield 2021 -
Capitalization 266 M 266 M -
Capi. / Sales 2021 26,7x
Capi. / Sales 2022 20,3x
Nbr of Employees 11
Free-Float 94,6%
Chart XOMA CORPORATION
Duration : Period :
XOMA Corporation Technical Analysis Chart | XOMA | US98419J2069 | MarketScreener
Technical analysis trends XOMA CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 23,51 $
Average target price 44,67 $
Spread / Average Target 90,0%
EPS Revisions
Managers and Directors
James R. Neal Chief Executive Officer & Director
Thomas Burns Chief Financial Officer & Senior VP-Finance
W. Denman van Ness Chairman
Jack L. Wyszomierski Independent Director
Joseph M. Limber Independent Director
Sector and Competitors
1st jan.Capi. (M$)
XOMA CORPORATION-46.73%266
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202